TGen: An Affiliate of City of Hope
City of Hope has joined forces with the Translational Genomics Research Institute (TGen) to accelerate the speed with which scientists and medical staff convert research discoveries into cures for patients.
The alliance is based on a simple premise: City of Hope provides a state-of-the-art clinical setting in which to advance genomic breakthroughs made by TGen.
It is a collaboration that plays to the strengths of each organization. City of Hope is a pioneer in the fields of bone marrow transplantation, hematologic malignancies, select solid tumors and diabetes. TGen, meanwhile, is a leader in applying genomic analysis and bioinformatics to cancer drug development.
Together, they are transforming the diagnosis, treatment and prevention of cancer and other life-threatening diseases.
It's all part of the organizations' efforts to augment their expertise in precision medicine, a rapidly evolving field that involves using an individual’s underlying genetic profile to guide clinical decisions, including the diagnosis and treatment of disease.
This alliance provides City of Hope with access to TGen's innovative genomics technologies, helping physicians and researchers move research discoveries into the clinic for the benefit of patients.
What Is Precision Medicine?
Precision medicine has emerged as a primary approach for disease prevention and the treatment of complex conditions. It is being explored for conditions such as cancer, neurological disorders and diabetes, to name a few.
- Researchers use individual variations in genes, environment and lifestyle to develop diagnostics, prognostics and therapies to target, treat and monitor chronic and life-threatening conditions.
The ability to better diagnose, treat, cure and prevent diseases depends on:
- Understanding the genetic cause of the diseases
- Understanding why individuals respond to different therapies
- Understanding who is at highest risk for different diseases
- Translating this information into new targeted diagnostic tests, therapeutics and the ability to detect disease early and track its progression specific to the individual
City of Hope and TGen’s combined strengths will propel us to the forefront of this emerging field.
Liquid Biopsy Offers a New Way to Target Kidney Cancer
February 17, 2017
Advances: New Immunotherapy Treatments for Breast Cancer in 2017
December 23, 2016
Cancer Insights: Molecular profiling unlocks tumor answers
October 27, 2016
Leukemia 2016: More treatments will target leukemia by type
December 31, 2015